Edition:
United Kingdom

Biomerieux SA (BIOX.PA)

BIOX.PA on Paris Stock Exchange

74.74EUR
12 Dec 2017
Change (% chg)

€0.02 (+0.03%)
Prev Close
€74.72
Open
€74.54
Day's High
€74.80
Day's Low
€74.01
Volume
127,013
Avg. Vol
142,572
52-wk High
€75.39
52-wk Low
€45.00

Chart for

About

Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial... (more)

Overall

Beta: 0.36
Market Cap(Mil.): €8,348.02
Shares Outstanding(Mil.): 118.36
Dividend: 0.33
Yield (%): 0.47

Financials

  Industry Sector
P/E (TTM): -- 32.16 16.44
EPS (TTM): -- -- --
ROI: -- 14.01 10.62
ROE: -- 16.85 14.20

BRIEF-Veneto Banca seals deal with Attestor over BIM stake sale

* signed an agreement with Trinity Investments Designated Activity Company, an investment company managed by Attestor Capital, over sale of its stake in BIM

25 Oct 2017

BRIEF-Biomerieux Q3 sales up at ‍​1.67 billion euros

* Q3 SALES EUR ‍​1.67 BILLION VERSUS EUR 1.51 BILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

18 Oct 2017

European stocks bounce back as strong earnings in focus

LONDON Investors piled back into European stocks on Wednesday, boosting indexes higher in a rally a day after geopolitical concern caused a drop across equity markets.

30 Aug 2017

European stocks bounce back as strong earnings in focus

LONDON Investors piled back into European stocks on Wednesday, boosting indexes higher in a rally a day after geopolitical concern caused a drop across equity markets.

30 Aug 2017

UPDATE 2-European stocks bounce back as strong earnings in focus

* Second quarter earnings to grow 16 pct - TR (Adds closing prices)

30 Aug 2017

European stocks bounce back as strong earnings in focus

LONDON, Aug 30 Investors piled back into European stocks on Wednesday, boosting indexes higher in a relief rally after geopolitical concerns caused a sharp dip across equity markets.

30 Aug 2017

BRIEF-Biomerieux H1 operating income rises to 163 million euros

* IS NOW TARGETING ORGANIC SALES GROWTH FOR FULL YEAR OF BETWEEN 9 PCT AND 10 PCT

30 Aug 2017

BRIEF-Bim Q2 net profit rises 50% to 216.4 mln lira, revises 2017 revenue growth outlook to 20-23%

* REPORTED ON MONDAY Q2 REVENUE OF 6.21 BILLION LIRA VERSUS 4.91 BILLION LIRA YEAR AGO

15 Aug 2017

BRIEF-Biomérieux receives FDA clearance for expanded pathogen identification capability on VITEK® MS

* BIOMÉRIEUX RECEIVES FDA CLEARANCE FOR EXPANDED PATHOGEN IDENTIFICATION CAPABILITY ON VITEK® MS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

31 Jul 2017

BRIEF-Sysmex and Biomérieux agreed to dissolve JV Sysmex Biomérieux co., ltd.

* SYSMEX AND BIOMÉRIEUX AGREED TO DISSOLVE THE JOINT VENTURE SYSMEX BIOMÉRIEUX CO., LTD.

27 Jul 2017

Earnings vs. Estimates